Table 6 (A) Multivariate backward stepwise Cox regression on OS Training-Validation (N = 258, including 2 cases with NA entries). (B) Multivariate backward stepwise Cox regression on OS whole ACRG (N = 300, including 3 cases with NA entries)
From: A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma
Hazard ratio | P value | |
|---|---|---|
(A) (N = 258) | ||
N stage | ||
0 | 1.00 | 1.000 |
1 | 2.77 (1.04–7.39) | 0.042 |
2 | 2.06 (0.77–5.47) | 0.149 |
3a | 4.50 (1.75–11.56) | 0.002 |
3b | 8.78 (3.36–22.90) | < 0.001 |
Chemotherapy | 0.48 (0.31–0.75) | 0.001 |
SCRG1 | 1.21 (1.11–1.32) | < 0.001 |
(B) (N = 300) | ||
T stage | ||
T2-3 | 1.00 | 1.000 |
T4a | 1.51 (1.03–2.20) | 0.034 |
T4b | 1.61 (0.91–2.85) | 0.104 |
N stage (6th AJCC) | ||
N0 | 1.00 | 1.000 |
N1 | 1.71 (0.84–3.48) | 0.143 |
N2 | 2.92 (1.42–6.00) | 0.004 |
N3 | 5.14 (2.45–10.81) | 0.000 |
MLH1 positivity | 1.60 (1.00–2.57) | 0.051 |
Chemotherapy | 0.43 (0.28–0.66) | 0.000 |
SCRG1 | 1.14 (1.05–1.24) | 0.001 |